Ion channel TRPV1-dependent activation of PTP1B suppresses EGFR-associated intestinal tumorigenesis

Area of Science:

• Gastroenterology
• Oncology
• Molecular Biology

Background:

• The intestinal epithelium regenerates rapidly, and disruptions in this process can lead to tumor formation.
• Negative regulators of oncogenic events in the intestinal epithelium are not fully understood.
• Epidermal Growth Factor Receptor (EGFR) is a key mediator of intestinal cell proliferation.

Purpose of the Study:

• To investigate the role of Transient Receptor Potential Vanilloid 1 (TRPV1) in regulating intestinal epithelial cell proliferation and tumor development.
• To elucidate the feedback loop between EGFR and TRPV1 in intestinal epithelial cells (IECs).

Main Methods:

• Investigated TRPV1 expression and activation in IECs upon EGFR stimulation.
• Utilized a murine model of intestinal neoplasia (Apc(Min/+) mice) to study the effects of TRPV1 deficiency and pharmacological interventions.
• Administered TRPV1 agonists and cyclooxygenase-2 (COX-2) inhibitors in mouse models.

Main Results:

• TRPV1 is expressed in IECs and activated by EGFR stimulation.
• TRPV1 activation inhibits EGFR-induced proliferation via Ca2+/calpain and Protein Tyrosine Phosphatase 1B (PTP1B) activation.
• TRPV1 deficiency exacerbated adenoma formation in Apc(Min/+) mice.
• EGFR kinase inhibitor treatment reversed protumorigenic phenotypes in TRPV1-deficient mice.
• TRPV1 agonist administration suppressed intestinal tumorigenesis, with combined effects with a COX-2 inhibitor.

Conclusions:

• TRPV1 acts as a negative regulator of EGFR signaling in the intestinal epithelium.
• TRPV1 activation suppresses intestinal tumorigenesis through PTP1B.
• Targeting TRPV1, potentially in combination with COX-2 inhibitors, represents a promising therapeutic strategy for intestinal tumor prevention.